Abstract
Cancer immunotherapy using antibodies that target immune checkpoints has delivered outstanding results. However, responses only occur in a subset of patients. A lack of understanding what biological processes determine an effective outcome has hindered the identification of reliable biomarkers, as well as the development of rational combination treatments. In this thesis I dissect the molecular events associated with responsiveness to immune checkpoint blockade, in order to identify predictive biomarkers and therapeutic targets to manoeuvre the immune response in the direction of tumour regression, to improve response rates.
Original language | English |
---|---|
Qualification | Doctor of Philosophy |
Awarding Institution |
|
Supervisors/Advisors |
|
Thesis sponsors | |
Award date | 13 Jun 2019 |
DOIs | |
Publication status | Unpublished - 2019 |
Embargo information
- Embargoed from 20/06/2019 to 01/06/2021. Made publicly available on 01/06/2021.